We provide you with 20 years of free, institutional-grade data for GOSS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GOSS. Explore the full financial landscape of GOSS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Hasnain Faheem | Grant, award...etc | 280,000 | 2026-01-05 | ||
| Giraudo Bryan | Grant, award...etc | 115,750 | 2026-01-05 | ||
| Smith Robert Paul JR | Grant, award...etc | 93,750 | 2026-01-05 | ||
| Aranda Richard | Grant, award...etc | 93,750 | 2026-01-05 | ||
| Peterson Caryn | Grant, award...etc | 84,500 | 2026-01-05 | ||
| Christian Waage | Grant, award...etc | 84,500 | 2026-01-05 | ||
| Giraudo Bryan | Grant, award...etc | 181,250 | 2025-10-02 | ||
| Aranda Richard | Grant, award...etc | 162,500 | 2025-10-02 | ||
| Hasnain Faheem | Grant, award...etc | 437,500 | 2025-10-02 | ||
| Peterson Caryn | Grant, award...etc | 125,000 | 2025-10-02 | ||
| Smith Robert Paul JR | Grant, award...etc | 162,500 | 2025-10-02 | ||
| Christian Waage | Grant, award...etc | 125,000 | 2025-10-02 | ||
| Milligan Sandra | Open Market Purchase | 26,050 | $1.92 | 2025-08-20 | |
| Aranda Richard | Sale | -1,908 | $0.66 | $1,260 | 2024-06-25 |
| Hasnain Faheem | Open Market Purchase | 372,000 | $0.67 | 2024-06-24 | |
| Giraudo Bryan | Open Market Purchase | 100,000 | $0.59 | 2024-06-20 | |
| Smith Robert Paul JR | Open Market Purchase | 25,000 | $0.6 | 2024-06-20 | |
| Christian Waage | Sale | -6,430 | $1.16 | $7,430 | 2024-03-28 |
| Giraudo Bryan | Sale | -6,430 | $1.16 | $7,431 | 2024-03-28 |
| Hasnain Faheem | Sale | -23,172 | $1.16 | $26,773 | 2024-03-28 |
| Aranda Richard | Sale | -4,018 | $1.33 | $5,342 | 2024-03-19 |
| Peterson Caryn | Sale | -4,018 | $1.33 | $5,343 | 2024-03-19 |
| Milligan Sandra | Open Market Purchase | 32,000 | $0.79 | 2023-11-17 | |
| Giraudo Bryan | Open Market Purchase | 200,000 | $0.56 | 2023-11-14 | |
| Christian Waage | Grant, award...etc | 16,880 | $0.13 | 2023-07-26 | |
| Hasnain Faheem | Grant, award...etc | 675,220 | $0.13 | 2023-07-26 | |
| Giraudo Bryan | Grant, award...etc | 67,525 | $0.13 | 2023-07-26 | |
| Aranda Richard | Sale | -1,814 | $1.29 | $2,340 | 2023-06-26 |
| Giraudo Bryan | Open Market Purchase | 55,000 | $1.02 | 2023-04-05 | |
| Christian Waage | Open Market Purchase | 18,500 | $1.2 | 2023-03-22 | |
| Giraudo Bryan | Open Market Purchase | 50,000 | $0.97 | 2023-03-22 | |
| Hasnain Faheem | Open Market Purchase | 878,572 | $1.03 | 2023-03-22 | |
| Carter Laura | Sale | -6,029 | $1.1 | $6,620 | 2023-03-20 |
| Aranda Richard | Sale | -7,563 | $1.1 | $8,304 | 2023-03-20 |
| Peterson Caryn | Sale | -7,564 | $1.1 | $8,305 | 2023-03-20 |
| Carter Laura | Sale | -4,876 | $12.07 | $58,868 | 2022-10-27 |
| Peterson Caryn | Sale | -4,757 | $12.07 | $57,431 | 2022-10-25 |
| Carter Laura | Sale | -4,876 | $12.07 | $58,868 | 2022-10-25 |
| Aranda Richard | Sale | -4,757 | $12.07 | $57,431 | 2022-10-25 |
| Carter Laura | Open Market Purchase | 6,934 | $7.21 | 2022-07-15 | |
| Christian Waage | Open Market Purchase | 6,934 | $7.21 | 2022-07-15 | |
| Giraudo Bryan | Open Market Purchase | 13,869 | $7.21 | 2022-07-15 | |
| Hasnain Faheem | Open Market Purchase | 138,696 | $7.21 | 2022-07-15 |
The information provided in this report about GOSS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Gossamer Bio, Inc(NASDAQ:GOSS) 
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor...
Website: http://www.gossamerbio.com
Founded: 2015
Full Time Employees: 171
Sector: Healthcare
Industry: Biotechnology